Personal injury litigation over diabetes drugs made by a Johnson & Johnson subsidiary will head to New Jersey (In re Invokana (Canagliflozin) Prod. Liab. Litig., J.P.M.L., No. 2750, 12/7/16).
Plaintiffs sued J&J and subsidiary Janssen Pharmaceuticals, Inc. alleging they failed to warn Invokana and Invokamet can cause kidney disease.
The U.S. Judicial Panel on Multidistrict Litigation said the Invokana/Invokamet suits share common issues, warranting a consolidated federal proceeding.
But the panel declined to include suits involving Farxiga or Jardiance, diabetes drugs in the same class as the Janssen products.
Farxiga is ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.